Thomas Gräser

No ORCID on file · 5 papers in corpus
rct 2008
Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate
Contraception ·doi:10.1016/j.contraception.2008.10.010

BACKGROUND: Acne is a multifactorial disease characterized by androgenic stimulation of sebaceous glands. Therefore, combined oral contraceptives (COCs) containing anti-androgenic progestogens are suitable candidates for acne treatment. Thi…

rct 2004
Mammographic breast density, hormones, and growth factors during continuous combined hormone therapy
Fertility and sterility ·doi:10.1016/j.fertnstert.2004.02.096

OBJECTIVE: To study the effect on mammographic breast density of two different continuous combined regimens for hormone therapy. DESIGN: Randomized clinical study. SETTING: University hospital. PATIENT(S): Postmenopausal women without an…

rct 2003
Effects of hormone replacement therapy on perceptual and cognitive event-related potentials in menopausal insomnia
Psychoneuroendocrinology ·doi:10.1016/s0306-4530(02)00032-x

The influence of a combined estrogen-progestin regimen (Climodien, Lafamme) on auditory event-related potentials (ERPs) was investigated in a double-blind, placebo-controlled, comparative, randomized 3-arm trial phase (Climodien 2/3=estradi…

rct 2003
Insomnia related to postmenopausal syndrome and hormone replacement therapy: sleep laboratory studies on baseline differences between patients and controls and double-blind, placebo-controlled investigations on the effects of a novel estrogen-progestogen combination (Climodien, Lafamme) versus estrogen alone
Journal of sleep research ·doi:10.1046/j.1365-2869.2003.00356.x

Differences in sleep and awakening quality between 51 insomniac postmenopausal syndrome patients and normal controls were evaluated. In a subsequent double-blind, placebo-controlled, comparative, randomized, three-arm trial (Climodien 2/3 =…

rct 2001
Effect on biochemical vasoactive markers during postmenopausal hormone replacement therapy: estradiol versus estradiol/dienogest
Maturitas ·doi:10.1016/s0378-5122(01)00169-4

OBJECTIVES: Aim was to compare the effects of estradiol-only therapy with combined estradiol/progestin treatment on the excretion of vasoactive mediators surrogating on possible effects in the vascular system. The progestin used was dienoge…